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Abstract
ADP is the cognate agonist of the P2Y1, P2Y12, and P2Y13 receptors. With the goal of identifying
a high potency agonist that selectively activates the P2Y1 receptor, we examined the
pharmacological selectivity of the conformationally constrained non-nucleotide analog (N)-
methanocarba-2MeSADP [(1′S,2′R, 3′S,4′R,5′S)-4-[(6-amino-2-methylthio-9H-purin-9-yl)-1-
diphosphoryloxymethyl]bicyclo[3.1.0]hexane-2,3-diol] among the three ADP-activated receptors.
Each P2Y receptor was expressed transiently in COS-7 cells, and inositol lipid hydrolysis was
quantified as a measure of receptor activity. In the case of the Gi-linked P2Y12 and P2Y13
receptors, a chimeric G protein, Gαq/i, was coexpressed to confer a capacity of these Gi-linked
receptors to activate phospholipase C. 2MeSADP (2-methylthio-ADP) was a potent agonist at all
three receptors exhibiting EC50 values in the sub to low nanomolar range. In contrast, whereas
(N)-methanocarba-2MeSADP was an extremely potent (EC50 = 1.2 ± 0.2 nM) agonist at the P2Y1
receptor, this non-nucleotide analog exhibited no agonist activity at the P2Y12 receptor and very
low activity at the P2Y13 receptor. (N)-Methanocarba-2MeSADP also failed to block the action of
2MeSADP at the P2Y12 and P2Y13 receptors, indicating that the (N)-methanocarba analog is not
an antagonist at these receptors. The P2Y1 receptor selectivity of (N)-methanocarba-2MeSADP
was confirmed in human platelets where it induced the shape change promoted by P2Y1 receptor
activation without inducing the sustained platelet aggregation that requires simultaneous activation
of the P2Y12 receptor. These results provide the first demonstration of a high-affinity agonist that
discriminates among the three ADP-activated P2Y receptors, and therefore, introduce a potentially
important new pharmacological tool for delineation of the relative biological action of these three
signaling proteins.
The G protein-coupled P2Y receptor family is comprised of at least eight different human
receptors that are activated by nucleoside diphosphates, nucleoside triphosphates, or
nucleotide sugars to regulate a broad range of physiological responses including
neurotransmission, muscle contraction, ion secretion, and platelet aggregation (Dubyak and
El-Moatassim, 1993; Harden et al., 1998; Ralevic and Burnstock, 1998). A complex set of
ectoenzymes that metabolize extracellular nucleotides has complicated the study of these
receptors (Harden et al., 1997; Zimmermann, 2000). This difficulty is exacerbated by the
lack of selective agonists or antagonists for most of the P2Y receptors.
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ADP is the cognate agonist of the P2Y1, P2Y12, and P2Y13 receptors. Whereas the P2Y1
receptor is coupled to Gq and activates phospholipase C, the P2Y12 and P2Y13 receptors are
coupled to Gi, inhibit adenylyl cyclase, and regulate ion channels (Harden et al., 1998;
Hollopeter et al., 2001). ADP promotes platelet aggregation through a complex and
incompletely defined interplay of cell signaling responses promoted by the P2Y1 and P2Y12
receptors (Kunapuli, 1998; Gachet, 2001). Although P2Y1 and P2Y12 receptor-selective
antagonists exist (Gachet, 2003), molecules that selectively activate individual subtypes of
the three member ADP receptor family have not been reported.
Our studies of bisphosphate antagonists of the P2Y1 receptor led to the discovery that the
ribose moiety was dispensible in these molecules and could be replaced by a variety of
carbocyclic or acyclic groups (Kim et al., 2000; Nandanan et al., 2000). Substitution of the
ribose ring of bisphosphate molecules with a pseudoribose consisting of cyclopentane and
cyclopropane rings fused in the methanocarba modification results in non-nucleotide
analogs containing a pseudoribose fixed in either a Northern or Southern envelope
conformation and in antagonist activity of sufficiently high selectivity and affinity (Kim et
al., 2001; Boyer et al., 2002) to be utilized in a radioligand binding assay for the P2Y1
receptor (Waldo et al., 2002). (N)-Methanocarba-ATP and (N)-methanocarba-UTP are
potent P2Y receptor agonists (Kim et al., 2002). Moreover, the high potency of (N)-
methanocarba-2MeSADP observed at the human P2Y1 receptor in initial studies (Ravi et al.,
2002) has prompted us to carry out a detailed comparison of the pharmacological activity of
this analog at the P2Y1 receptor versus activity at the ADP-activated P2Y12 and P2Y13
receptors. Our results illustrate high selectivity of (N)-methanocarba-2MeSADP for the
P2Y1 receptor. Furthermore, they demonstrate the usefulness of (N)-
methanocarba-2MeSADP to, for example, effect independent activation of the platelet P2Y1
receptor under conditions that do not necessitate simultaneous blockade of the platelet
P2Y12 receptor.
Materials and Methods
Transfection of COS-7 Cells and Quantification of P2Y Receptor-Stimulated Phospholipase
C Activity
COS-7 cells were seeded in 12-well culture dishes at a density of approximately 60,000 cells
per well and maintained in high glucose Dulbecco’s modified Eagle’s medium containing
10% fetal bovine serum, 100 U/ml penicillin, and 100 μg/ml streptomycin at 37°C in an
atmosphere of 90% air/10% CO2. The indicated DNA vectors (in pcDNA3.1) were
transfected using Fugene 6 (Roche Diagnostics, Indianapolis, IN) transfection reagent (3 μl
of Fugene/1 μg of DNA) according to the manufacturer’s protocol. The human P2Y12 and
P2Y13 receptor DNA vectors (200 ng/well) were cotransfected with a DNA vector for Gαq/i
(100 ng/well). Gαq/i is a chimeric construct of Gα subunits that confers to Gi-linked
receptors a capacity to activate Gq and phospholipase C-β, and therefore, to promote inositol
lipid hydrolysis in response to agonist-promoted receptor activation (Conklin et al., 1992).
An expression vector for the human P2Y1 receptor, which couples to Gq and phospholipase
C-β (Schachter et al., 1996; Waldo and Harden, 2004), was transfected (200 ng/well) in
COS-7 cells in the absence of Gαq/i.
Approximately 24 h after transfection, the culture medium was changed to inositol-free
Dulbecco’s modified Eagle’s medium (ICN Biomedicals Inc., Costa Mesa, CA) containing 1
μCi/well myo-[2-3H]inositol (American Radiolabeled Chemicals, St. Louis, MO), and
metabolic labeling proceeded for 12 to 16 h. Agonist-promoted accumulation of [3H]inositol
phosphates was quantified subsequent to addition of 10 mM LiCl to inhibit inositol
phosphate phosphatases. The reaction was stopped after 60 min by aspiration of the medium
and the addition of 50 mM formic acid followed by neutralization with 150 mM NH4OH.
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[3H]Inositol phosphates were quantified by Dowex chromatography as previously described
(Brown et al., 1991).
Preparation and Assay of Washed Human Platelets
Blood was collected from healthy volunteers into syringes containing one-sixth final blood
volume of anticoagulant (65 mM citric acid, 85 mM sodium citrate, and 110 mM dextrose).
The blood was centrifuged at 180g for 15 min, and the supernatant (platelet rich plasma)
was removed. The platelet rich plasma was centrifuged, and the platelets were resuspended
in a buffer consisting of 137 mM NaCl, 2.7 mM KCl, 2 mM CaCl2, 1 mM MgCl2, 3 mM
NaH2PO4, 5 mM glucose, 10 mM HEPES (pH 7.4), and 0.2% bovine serum albumin. These
centrifugations and washes were repeated twice followed by a final resuspension in the
medium described above containing 0.25 U/ml apyrase. Platelet aggregation was measured
using the optical mode of a Chrono-Log aggregometer (Chrono-Log Corporation,
Havertown, PA). Four hundred and fifty microliters of platelet suspension containing 1 mg/
ml fibrinogen were warmed to 37°C and stirred at 1000 rpm. Indicated concentrations of
drugs were added to the sample, and aggregation was monitored for 8 min. Two
modifications were included to obtain accurate estimations of platelet shape change. The
offset mode of the Aggro/Link computer interface was applied, and the reference sample
cuvette of the aggregometer included a platelet suspension equivalent to 50% of that present
in cuvettes for drug testing.
Synthesis of (N)-Methanocarba-2MeSADP
(N)-Methanocarba-2MeSADP (MRS2365; Fig. 1) was synthesized as previously described




To compare the pharmacological selectivities of the ADP-activated human P2Y1, P2Y12,
and P2Y13 receptors, we generated mammalian expression constructs for each of these
receptors and transiently expressed these G protein-coupled receptors in COS-7 cells. The
Gαq-coupled P2Y1 receptor was expressed alone, whereas the Gαi-coupled P2Y12 and
P2Y13 receptors were coexpressed with a chimeric construct of Gαq, which incorporates the
last five amino acids of Gαi1 at the carboxy terminus and consequently confers capacity of
Gi-linked receptors to activate Gαq and phospholipase C-β (Conklin et al., 1992). Therefore,
[3H]inositol phosphate accumulation was quantified as a measure of activation of each of the
three different P2Y receptors.
Although 2MeSADP exhibited little or no effect in empty vector-transfected COS-7 cells
(data not shown), marked concentration-dependent stimulation of inositol lipid hydrolysis
occurred in response to 2MeSADP in cells transiently expressing the P2Y1 receptor (Fig.
2A). We recently reported the synthesis and biological testing of a series of methanocarba
analogs of adenine and uridine nucleotides (Ravi et al., 2002). These conformationally
constrained non-nucleotide molecules retain, in several instances, a capacity to activate P2Y
receptors. For example, (N)-methanocarba-2MeSADP activated the human P2Y1 receptor
stably expressed in 1321N1 human astrocytoma cells with the highest potency (EC50 = 0.4
nM) yet reported for activation of this receptor. This high potency of (N)-
methanocarba-2MeSADP also was observed after transient expression of the human P2Y1
receptor in COS-7 cells (Fig. 2A) where (N)-methanocarba-2MeSADP exhibited a potency
(EC50 = 1.8 ± 1.0 nM; mean ± S.D. of n = 3 experiments) approximately 4-fold higher than
that of 2MeSADP (EC50 = 6.6 ± 3.0 nM; mean ± S.D.; n = 3 experiments).
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Expression of the human P2Y12 receptor in COS-7 cells failed to confer an inositol
phosphate response to 2MeSADP in these cells (data not shown). In contrast, coexpression
of the P2Y12 receptor with Gαq/i resulted in robust 2MeSADP-promoted inositol lipid
hydrolysis (Fig. 2B). The potency of 2MeSADP (0.3 ± 0.2 nM; mean ± S.D. of n = 3
experiments) was approximately 10-fold greater than that observed with the human P2Y1
receptor. In marked contrast to the activity observed at the human P2Y1 receptor, (N)-
methanocarba-2MeSADP exhibited no agonist activity at the P2Y12 receptor (Fig. 2B). (N)-
Methanocarba-2MeSADP also was not an antagonist at the P2Y12 receptor since a 10 μM
concentration of this analog exhibited no effect on the capacity of 1 nM 2MeSADP to
stimulate inositol phosphate accumulation (data not shown).
Expression of the human P2Y13 receptor in COS-7 cells failed to confer an inositol
phosphate response to 2MeSADP in these cells (data not shown). As was observed with the
P2Y12 receptor, coexpression of the P2Y13 receptor with Gαq/i conferred marked inositol
lipid signaling responses to 2MeSADP (Fig. 2C). In contrast, little or no response to (N)-
methanocarba-2MeSADP occurred. The results depicted in Fig. 2C represent the largest
effect observed in four different experiments in which full concentration-effect curves were
generated for activation of the P2Y13 receptor; essentially no effect was observed in the
other three experiments. The stimulatory activity of 1 nM 2MeSADP also was not
antagonized by 10 μM (N)-methanocarba-2MeSADP indicating that this analog is neither a
partial agonist nor an antagonist at the P2Y13 receptor (data not shown).
To further confirm the large difference in response of the P2Y1 receptor versus the P2Y12
and P2Y13 receptors to (N)-methanocarba-2MeSADP, we carried out a series of experiments
in which the response to this novel agonist was tested simultaneously at the three different
ADP-activated P2Y receptors. Whereas the level of activation of the P2Y1 receptor observed
with 10, 100, and 1000 nM concentrations of (N)-methanocarba-2MeSADP was essentially
equivalent to that of a maximally effective concentration of 2MeSADP, no significant
activation of the P2Y12 receptor or P2Y13 receptor was observed at these concentrations of
(N)-methanocarba-2MeSADP (Fig. 3).
The physiological response of platelets to ADP involves the coordinated action of an ADP-
activated P2Y1 receptor and an ADP-activated P2Y12 receptor. Thus, shape change and
transient aggregation occurs upon activation of the P2Y1 receptor alone, but full and
sustained aggregation requires activation of both the P2Y1 and P2Y12 receptors. Given the
P2Y1 receptor-selective action of (N)-methanocarba-2MeSADP revealed in our studies with
recombinant human receptors, we tested the action of this analog in studies with human
platelets. Whereas the addition of 2MeSADP to washed human platelets caused the transient
shape change and marked and sustained aggregation responses that have been widely
reported to occur with ADP and 2MeSADP (Fig. 4), addition of (N)-
methanocarba-2MeSADP only resulted in a shape change with no accompanying
aggregation. The rapid shape change was sustained for at least 6 min of incubation with (N)-
methanocarba-2MeSADP without any evidence of aggregation (Fig. 4). However,
2MeSADP-induced plateletaggregation still occurred if platelets were preincubated for 2
min with 1 μM (N)-methanocarba-2MeSADP prior to the addition of 2MeSADP (Fig. 4).
The concentration dependence of (N)-methanocarba-2MeSADP for inducing shape change
was determined (Fig. 5). Measurable effects were observed with 1 nM (N)-
methanocarba-2MeSADP, and maximal shape change occurred with 10 to 30 nM (N)-
methanocarba-2MeSADP. Platelet aggregation was not observed at any of the (N)-
methanocarba-2MeSADP concentrations tested.
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The P2Y1 receptor-selective action of (N)-methanocarba-2MeSADP on human platelets was
confirmed using the P2Y1 receptor-selective antagonist MRS2179 (Boyer et al., 1998).
Thus, although addition of 10 μM MRS2179 alone had no measurable effect on platelets,
concentrations (1–100 nM) of (N)-methanocarba-2MeSADP that caused platelet shape
change in the absence of antagonist had no effect in the presence of 10 μM MRS2179 (Fig.
6). The effects of MRS2179 were surmountable by higher concentrations of (N)-
methanocarba-2MeSADP, and a maximal shape change was observed with 300 nM (N)-
methanocarba-2MeSADP in the presence of 10 μM MRS2179. These primary response data
were utilized to generate concentration-effect curves for (N)-methanocarba-2MeSADP (Fig.
7) and revealed an approximately two order of magnitude shift to the right of the
concentration-effect curve of (N)-methanocarba-2MeSADP for induction of platelet shape
change. Since these experiments were carried out with a concentration of MRS2179 that
exceeds its KB by approximately 100-fold, the results are consistent with the expected effect
of a competitive P2Y1 receptor antagonist blocking the action of the P2Y1 receptor agonist
(N)-methanocarba-2MeSADP.
Discussion
ADP is the cognate agonist of the P2Y1, P2Y12, and P2Y13 receptors, which also are
potently activated by 2MeSADP (Harden et al., 1998; Ralevic and Burnstock, 1998;
Communi et al., 2001; Hollopeter et al., 2001). We show here that whereas the P2Y1
receptor is activated by subnanomolar concentrations of (N)-methanocarba-2MeSADP,
neither the P2Y12 nor the P2Y13 receptor is sensitive to activation by this non-nucleotide
agonist. Therefore, a molecule has been identified that selectively binds and activates a
member of the ADP-activated P2Y receptor family without exhibiting either agonist or
antagonist action at the other two G protein-coupled receptors that comprise this subfamily
of P2Y receptors. Our additional demonstration of activation of the platelet P2Y1 receptor
without concurrent activation of the platelet P2Y12 receptor provides an initial glimpse of
the potential usefulness of this conformationally constrained P2Y1 receptor-selective agonist
for study of P2Y receptor-promoted signaling in mammalian tissues.
The molecular identification of the P2Y12 receptor (Hollopeter et al., 2001) and subsequent
identification of the P2Y13 receptor (Communi et al., 2001), confirmed the previously held
notion that activation of the P2Y1 receptor did not completely account for ADP-stimulated
responses in glioma cells (Boyer et al., 1993, 1994; Schachter et al., 1997), in platelets
(Fagura et al., 1998; Hechler et al., 1998; Jin and Kunapuli, 1998; Jin et al., 1998), and in
other tissues. This was of particular importance to platelet biology since ADPpromotes
platelet aggregation (Gachet and Cazenave, 1991), since human pathophysiologies related to
platelet function may involve the ADP receptors or their downstream signaling cohorts
(Cattaneo and Gachet, 1999), and since the platelet receptors for ADP are important drug
targets (Cattaneo and Gachet, 1999; Gachet, 2003). Our discovery that bisphosphate
nucleotide analogs were highly selective competitive antagonists of the P2Y1 receptor
(Boyer et al., 1996, 1998) provided important reagents used to unravel the relative roles of
the ADP-activated P2Y1 receptor and another ADP-activated receptor (now known to be the
P2Y12 receptor) in the Gq- and Gi-mediated signaling responses, respectively, and in the
shape change and aggregation responses of platelets to ADP (Fagura et al., 1998; Hechler et
al., 1998; Jin and Kunapuli, 1998; Jin et al., 1998).
The identification of (N)-methanocarba-2MeSADP as an agonist that potently activates
P2Y1 but not P2Y12 or P2Y13 receptors now provides a pharmacological approach to
specifically activate the P2Y1 receptor in tissues that express both this receptor as well as the
P2Y12 and/or P2Y13 receptor. This obviously is a goal in pharmacological studies of ADP-
promoted responses of platelets, and our data with (N)-methanocarba-2MeSADP provide the
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first demonstration of independent activation of the P2Y1 receptor in a mammalian tissue
expressing multiple ADP-activated P2Y receptors. This selective agonist also may prove
important in studies in the central nervous system where both the P2Y1 (Webb and Barnard,
1999) and P2Y12 (Hollopeter et al., 2001) receptors are widely distributed.
Introduction of conformational constraints, in an otherwise freely flexible molecule,
potentially provides a powerful approach in ligand development. Lock of the conformation
of a biologically active molecule in its preferred geometry for association with a target
receptor may enhance pharmacological potency and selectivity, and molecular insight into
the conformational requirements of the binding site may be gleaned. In the case of P2Y
receptor ligands, we have reported that the (N)-conformation of the ribose or pseudoribose
moiety is accommodated or preferred at the P2Y1, P2Y2, P2Y4, or P2Y11 receptors, but not
at the P2Y6 receptor. This conclusion was based on the synthesis and pharmacological
characterization of both adenine and uracil nucleotide methanocarba derivatives. The present
study extends this analysis to the Gi-linked P2Y12 and P2Y13 receptors, which do not
recognize this analog locked in the (N)-conformation, thus placing these receptors in the
same category as the P2Y6 receptor. The structural basis for this distinction of
conformationally constrained analogs among the P2Y receptors is unclear, since recognition
of (N)-methanocarba analogs does not correspond to any obvious protein sequence
homology patterns among these receptors.
In the case of (N)-methanocarba-2MeSADP, we have illustrated that ring constrained (N)-
methanocarba substitution combined with another functionality increases both agonist
potency and, as illustrated here, receptor selectivity among ADP-activated P2Y receptors.
Combined with our previous results illustrating that (N)-methanocarba-2MeSADP does not
activate the Gq/phospholipase C-coupled P2Y2, P2Y4, P2Y6, and P2Y11 receptors (Ravi et
al., 2002), the current results have significant implications for development of agonists of
high potency and selectivity for other subfamilies of receptors within the P2Y receptor
family.
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Structure of 2MeSADP and (N)-methanocarba-2MeSADP.
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Agonist activities of 2MeSADP and (N)-methanocarba-2MeSADP at the human P2Y1,
P2Y12, and P2Y13 receptors. COS-7 cells transfected with mammalian expression vectors
for the human P2Y1, P2Y12, or P2Y13 receptors were preloaded with [3H]inositol, and
agonist-promoted inositol lipid hydrolysis was quantified as described under Materials and
Methods. Cells transfected with P2Y12 or P2Y13 receptor expression vectors also were
cotransfected with an expression vector for Gαq/i, which confers capacity of these two Gi-
coupled receptors to activate phospholipase C. Inositol phosphate responses were measured
to the indicated concentrations of 2MeSADP (▲) or (N)-methanocarba-2MeSADP (●) in
P2Y1 receptor expressing cells (A), P2Y12 receptor expressing cells (B), and P2Y13 receptor
expressing cells (C). The data are presented as counts per minute (mean ± S.E.M.; n = 3) of
[3H]inositol phosphate accumulation, and the results are representative of results obtained in
at least three full concentration-effect curves generated for both agonists with each receptor.
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Comparative response of P2Y1, P2Y12, and P2Y13 receptors to (N)-
methanocarba-2MeSADP. COS-7 cells expressing the P2Y1 receptor, the P2Y12 receptor +
Gαq/i, or the P2Y13 receptor + Gαq/i were challenged with the indicated concentrations of
(N)-methanocarba-2MeSADP. The response in each case is compared with that of a
maximally effective concentration (100 nM) of 2MeSADP, which was assigned a value of
100%. The results are the mean ± S.E.M. of four independent experiments carried out in
triplicate.
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Induction of shape change of human platelets by (N)-methanocarba-2MeSADP. Washed
human platelets were prepared, and drug-induced shape change (decrease in light
transmission) and aggregation (increase in light transmission) were quantified in an
aggregometer as described under Materials and Methods. Whereas addition of 30 nM
2MeSADP resulted in a transient shape change followed by platelet aggregation, addition of
1 or 10 μM (N)-methanocarba-2MeSADP only resulted in a rapidly occurring but sustained
shape change. Platelets incubated with 1 μM (N)-methanocarba-2MeSADP for 3 min still
responded with an aggregation response to 2MeSADP. These results are representative of
results obtained in three different experiments.
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Concentration-dependent induction of platelet shape change by (N)-
methanocarba-2MeSADP. Washed human platelets were prepared, and drug-induced shape
change (decrease in light transmission) in response to the indicated concentrations of (N)-
methanocarba-2MeSADP was quantified in an aggregometer as described under Materials
and Methods. The results are representative of those obtained in three separate experiments.
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Antagonism of (N)-methanocarba-2MeSADP-induced platelet shape change by the P2Y1
receptor antagonist MRS2179. Washed human platelets were prepared, and drug-induced
shape change (decrease in light transmission) and the capacity of the P2Y1 receptor
antagonist MRS2179 to antagonize the shape change response to the indicated
concentrations of (N)-methanocarba-2MeSADP was quantified in an aggregometer as
described under Materials and Methods. In each case, 10 μM MRS2179 was added for 2
min prior to the addition of (N)-methanocarba-2MeSADP. The results are representative of
those from three separate experiments.
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Concentration-effect curve for (N)-methanocarba-2MeSADP in the absence or presence of
MRS2179. The platelet shape change response was measured exactly as described in Fig. 5
for various concentrations of (N)-methanocarba-2MeSADP alone and in Fig. 6 for various
concentrations of (N)-methanocarba-2MeSADP in the presence of 10 μM MRS2179. The
resulting shape change tracings were transformed into concentration-effect curves by
quantifying the relative maximal shape change occurring 1 min after agonist addition in each
case. The results are presented as the average mean values (S.E.M. varied by less than 15%
for each value) from three experiments.
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